Nitisinone Coverage for Hereditary Tyrosinemia Type 1 and Alkaptonuria
Customize your policy alerts
Sign up for Molina Healthcare Policy C13398-A alerts
Get alerted when Policy C13398-A changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and coverage criteria for oral nitisinone products used for hereditary tyrosinemia type 1 and, for Harliku only, alkaptonuria. It applies to Molina members subject to benefit eligibility, formulary requirements, and documented clinical and monitoring criteria.
The Q3 2026 revision updated the products affected, diagnosis requirements, required medical information, continuation criteria, duration of approval, age restrictions, quantity, FDA-approved uses, background, and references.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.